Recent News

• 06.01.2026 - Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
• 04.21.2026 - Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Recent Filings

• 05.15.2026 - 424B7 Prospectus [Rule 424(b)(7)]
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - EX-99.1 EX-99.1
• 05.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2026 - 8-K Current report
• 04.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.30.2026 - DEF 14A Other definitive proxy statements
• 04.30.2026 - ARS Annual Report to Security Holders
• 04.29.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 04.29.2026 - EFFECT Notice of Effectiveness